Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 194-209 http://medscipublisher.com/index.php/cge 197 method to assess tumor dynamics, disease progression, and response to therapy. Advances in CTC detection technologies, such as microfluidic devices and immunomagnetic separation, have enhanced the sensitivity and specificity of CTC assays, making them valuable tools for clinical applications. CTCs can be isolated from blood samples and analyzed for various molecular characteristics, including gene expression profiles and protein markers. This allows for the identification of specific subpopulations of tumor cells that may be responsible for metastasis and treatment resistance. Studies have shown that high levels of CTCs are associated with poor prognosis and shorter overall survival in colon cancer patients. For example, Zhang et al. (2022) demonstrated that the presence of CTCs correlated with disease stage and could be used to monitor treatment efficacy and detect early signs of relapse. The integration of CTC analysis with other diagnostic modalities, such as ctDNA and imaging techniques, can provide a more comprehensive understanding of tumor biology and enhance the precision of cancer management. As CTC research advances, these cells are expected to become an integral part of liquid biopsy strategies, contributing to personalized treatment plans and improving patient outcomes. 3.3 Exosomes and microvesicles Exosomes and microvesicles are extracellular vesicles secreted by cells, including cancer cells, that contain a variety of biomolecules such as proteins, lipids, and nucleic acids. These vesicles play crucial roles in cell communication and can modulate various physiological and pathological processes. In the context of colon cancer, exosomes have emerged as promising non-invasive biomarkers due to their ability to carry tumor-specific information that reflects the molecular and cellular characteristics of the originating tumor. Exosomes can be isolated from body fluids like blood, urine, and saliva, and their content can be analyzed to identify biomarkers for cancer detection and monitoring. For instance, exosomal microRNAs (miRNAs) have been shown to regulate gene expression and play roles in cancer progression and metastasis. Chen et al. (2020) highlighted the potential of exosomal miRNAs as diagnostic and prognostic biomarkers in colon cancer, demonstrating that specific miRNA profiles could distinguish cancer patients from healthy individuals and predict disease outcomes. Moreover, exosomes can provide insights into the tumor microenvironment and the mechanisms of drug resistance, making them valuable for monitoring therapeutic responses and developing personalized treatment strategies. The analysis of exosomal proteins and RNA molecules can complement traditional diagnostic methods, offering a non-invasive approach to detect early-stage cancer and monitor disease progression. As research in this field progresses, exosomes and microvesicles are expected to play a significant role in the development of liquid biopsy techniques, improving the accuracy and efficacy of cancer diagnosis and management. 3.4 Non-coding RNAs Non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), are RNA molecules that do not encode proteins but play crucial roles in regulating gene expression. In colon cancer, dysregulation of specific ncRNAs has been implicated in tumor development, progression, and metastasis. These molecules can be detected in body fluids, making them attractive candidates for non-invasive biomarkers in cancer diagnosis and monitoring (Sadri et al., 2021). miRNAs are short, single-stranded RNA molecules that can regulate gene expression by binding to complementary sequences in target mRNAs, leading to their degradation or inhibition of translation. Several miRNAs have been identified as potential biomarkers for colon cancer. For example, Deng et al. (2017) reported that specific miRNA profiles in blood could distinguish colon cancer patients from healthy individuals and provide prognostic information. Similarly, lncRNAs, which are longer RNA molecules, have been shown to interact with various molecular pathways involved in cancer. Dong et al. (2019) demonstrated that the lncRNA HULC promotes colon cancer growth and metastasis by targeting miR-613, highlighting its potential as a therapeutic target and diagnostic marker.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==